Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth

Cancer Prevention Research

Volumn 6, Issue 5, 2013, Pages 455-465

  Lee, Mee Hyun ^a   Huang, Zunnan ^a,b   Kim, Dong Joon ^a,g   Kim, Sung Hyun ^c   Kim, Myoung Ok ^c   Lee, Sung Young ^a,e   Xie, Hua ^a,f   Park, Si Jun ^c   Kim, Jae Young ^c   Kundu, Joydeb Kumar ^d   Bode, Ann M ^a   Surh, Young Joon ^e   Dong, Zigang ^a,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c Kyungpook National University   (South Korea)

^d Keimyung University   (South Korea)

^e Seoul National University   (South Korea)

^f SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^g Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; S6 KINASE; SILIBININ; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; COMPUTER SIMULATION; ENZYME INHIBITORS; FEMALE; G1 PHASE; HETEROGRAFTS; HUMANS; IMMUNOENZYME TECHNIQUES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN CONFORMATION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SILYMARIN; TUMOR CELLS, CULTURED;

EID: 84877277024     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0425     Document Type: Article

References (33)

1. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55:490-500. (Pubitemid 44209289)
2. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 2012; 23 Suppl 8: viii10-4.
3. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666-74.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. (Pubitemid 34716871)
5. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200:362-70. (Pubitemid 40298970)
6. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 2003; 278:42409-18. (Pubitemid 37310512)
7. Jorgensen K, Holm R, Maelandsmo GM, Florenes VA. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 2003; 9:5325-31. (Pubitemid 37413587)
8. Miadonna A, Tedeschi A, Leggieri E, Lorini M, Froldi M, Zanussi C. Effects of silybin on histamine release from human basophil leucocytes. Br J Clin Pharmacol 1987; 24:747-52. (Pubitemid 18078377)
9. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 2001; 15:465-89. (Pubitemid 32783707)
10. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, et al. Silibinin upregulates the expression of cyclindependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003; 22: 8271-82. (Pubitemid 37485520)
11. Dagne A, Melkamu T, Schutten MM, Qian X, Upadhyaya P, Luo X, et al. Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice. Carcinogenesis 2011; 32:561-7.
12. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries n human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006; 25: 1053-69. (Pubitemid 43277013)
13. Ramasamy K, Dwyer-Nield LD, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, et al. Silibinin prevents lung tumorigenesis in wild-type but not n iNOS -/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res 2011; 17:753-61.
14. Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, Woo SK, et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther 2010; 9:3233-43.
15. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004; 25:1711-20. (Pubitemid 39214314)
16. Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang Z, et al. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 2011; 10: 104-16.
17. Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, et al. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Mol Cancer Ther 2010; 9:3330-41.
18. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28:235-42. (Pubitemid 30047768)
19. Pub Chem compound database. Available from: http://pubchem.ncbi.nlm.nih. gov
20. Schroödinger Suite 2011 Protein Preparation Wizard; Epik version 2.2, Schroödinger, LLC, New York, NY, 2011; Impact version 5.7, Schroödinger, LLC, New York, NY, 2011.
21. Schroödinger. Confgen version 2.3. New York, NY: LLC; 2011.
22. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47:1739-49. (Pubitemid 38380917)
23. Schroödinger. Glide version 5.7. New York, NY: LLC; 2011.
24. Schroödinger Suite 2011 Induced Fit Docking protocol; Glide version 5.7, Schroödinger, LLC, New York, NY, 2011; Prime version 3.0, Schroödinger, LLC, New York, NY, 2011.
25. Schroödinger. Maestro version 9.2. New York, NY: LLC; 2011.
26. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS ONE 2011; 6:e25806.
27. Flaherty KT, McArthur G. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 2010; 116:4902-13.
28. Smalley KS, McArthur GA. The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol 2012; 39:204-14.
29. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006; 49:6177-96. (Pubitemid 44595196)
30. Nakashima S, Matsuda H, Oda Y, Nakamura S, Xu F, Yoshikawa M. Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells. Bioorg Med Chem 2010; 18:2337-45.
31. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006; 147: 5699-707. (Pubitemid 44833486)
32. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203:1651-6. (Pubitemid 44036269)
33. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009; 106:4519-24.